InMed Pharmaceuticals Inc.
INM Nasdaq· Pharmaceutical Preparations
Last close · Oct 26, 2026
$1.59
KIRA · Stoqly’s AI analyst, in plain words
- InMed Pharmaceuticals Inc. lost $12.6M in fiscal 2026.
Market cap
$6.6M
P/E
—
Revenue
—
Net income
−$12.6M
Free cash flow
—
Operating margin
—
InMed Pharmaceuticals Inc. in 30 seconds · fiscal 2026
Does it make a profit?
−$12.6M
No. It lost money last year.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What InMed Pharmaceuticals Inc. does
No business description yet.
- Fiscal year ends
- June 30, 2026
- Latest annual report
- 10-K · Sep 9, 2026
- Legal name
- InMed Pharmaceuticals Inc.
- CIK
- 0001728328
InMed Pharmaceuticals Inc. · INM
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $1.1M | $4.1M | $4.6M | $4.9M | — |
| Revenue growth | −42.8% | 279.6% | 11.2% | 7.5% | — |
| Gross margin | 49.9% | 33.9% | 23.9% | 34.5% | — |
| Operating margin | −1,707.4% | −192.2% | — | — | — |
| Net income | −$18.6M | −$7.9M | −$7.7M | −$8.2M | −$12.6M |
| Net margin | −1,707.4% | −192.2% | −166.9% | −165.1% | — |
| Diluted EPS | −$33.17 | −$3.25 | −$20.14 | −$8.36 | −$3.12 |
| Cash | |||||
| Cash from operations | −$15.6M | −$7.3M | −$7.0M | −$8.1M | −$8.6M |
| Capital expenditure | $0.0M | $0.2M | $0.0M | — | — |
| Free cash flow | −$15.6M | −$7.4M | −$7.0M | — | — |
| FCF margin | −1,434.1% | −180.0% | −152.1% | — | — |
| Share count change | 108.6% | 336.6% | −84.4% | 156.1% | 326.6% |
| Debt and strength | |||||
| Cash and short-term investments | $6.2M | $9.0M | $6.6M | $10.8M | $2.2M |
| Shareholders' equity | $9.1M | $12.1M | $9.2M | $13.4M | $1.1M |
| Current ratio | 2.9x | 5.7x | 4.4x | 7.0x | 1.4x |
| Returns and quality | |||||
| Return on equity | −226.1% | −75.1% | −72.1% | −72.1% | −173.1% |
| Return on tangible equity | −266.9% | −78.4% | −103.4% | −69.1% | −1,208.6% |
| Piotroski F-score | 1 | 4 | 3 | 4 | — |
| Altman Z'' | −27.8 | −16.6 | — | — | — |
Insiders bought, 12 months
$1.4M
4 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
InMed Pharmaceuticals Inc. · INM
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $1.59 a share, the company is worth $6.6M.
Source: SEC EDGAR XBRL filings (CIK 0001728328). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.